RIL
TRDA icon

Rothschild Investment LLC’s Entrada Therapeutics TRDA Stock Holding History

Rothschild Investment LLC’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01K Buy
273
+253
+1,265% +$2.43K ﹤0.01% 2764
2026
Q1 		$252 Buy
20
+18
+900% +$206 ﹤0.01% 3263
2025
Q4 		$21 Buy
+2
New +$17 ﹤0.01% 3337
2025
Q2 		– Sell
-20
Closed -$181 – 3187
2025
Q1 		$181 Buy
+20
New +$249 ﹤0.01% 2874

Other funds holding TRDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Rothschild Investment LLC's TRDA Position: Q2 2026 in Review

Rothschild Investment LLC increased its Entrada Therapeutics (TRDA) stake by 1,265% in Q2 2026, buying an estimated $2.43K and bringing the position to 273 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Rothschild Investment LLC first reported a position in TRDA in Q1 2025 and has held it in 4 quarters since. 38 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Rothschild Investment LLC held 273 shares of Entrada Therapeutics worth $2.01K as of Q2 2026.
  • Rothschild Investment LLC bought 253 Entrada Therapeutics shares in Q2 2026, an estimated $2.43K.
  • Entrada Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2764 holding.
  • Rothschild Investment LLC first reported a position in Entrada Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 38 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.